Toxic epidermal necrolysis: The year in review

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 4, 2013, Pages 330-336

  Lee, Haur Yueh ^a   Chung, Wen Hung ^b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Granulysin; Pharmacogenetics; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ABACAVIR; ALLOPURINOL; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC FACTOR; FAS LIGAND; GRANULYSIN; GRANZYME; HLA A ANTIGEN; HLA B ANTIGEN; IMMUNOGLOBULIN; LAMOTRIGINE; METHAZOLAMIDE; OXCARBAZEPINE; OXICAM DERIVATIVE; PERFORIN; PHENYTOIN; SULFAMETHOXAZOLE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ASIAN; CELL INTERACTION; CYTOTOXIC T LYMPHOCYTE; DRESS SYNDROME; EARLY DIAGNOSIS; EFFECTOR CELL; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HUMAN; NATURAL KILLER CELL; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; STRUCTURAL HOMOLOGY; TOXIC EPIDERMAL NECROLYSIS;

ALLELES; CD8-POSITIVE T-LYMPHOCYTES; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; STEVENS-JOHNSON SYNDROME;

EID: 84880135461     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283630cc2     Document Type: Review

References (60)

1. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens- Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.
2. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J Invest Dermatol 2008; 128: 35-44.
3. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013; 1197-1204; online first 7 Feb. doi: 10.1038/JID.2012.510.
4. Roujeau JC, Stern R. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-1285.
5. Chung WH, Hung SL, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:426.
6. Chung WH, Hung SI. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatol Sci 2012; 66: 190-196.
7. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomincs J 2006; 6: 265-268.
8. Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B-1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75: 579-582.
9. Kaniwa N, Saito Y, Aihara M, et al. HLA-B-1511 is a risk factor for carbamazepine- induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010; 51: 2461-2465.
10. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B-1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010; 51: 926-930.
11. Ikeda H, Takahashi Y, Yamazaki E, et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010; 51: 297-300.
12. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepineinduced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
13. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identified HLA-A-3101 allele as a genetic risk factor for carbamazepineinduced cutaneous adverse drug reaction in Japanese population. Hum Mol Genet 2011; 20: 1034-1041.
14. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A-3101 and carbamazepine- induced hypersensitivity reactions in Europeans. N Eng J Med 2011; 364: 1134-1143.
15. Genin E, Chen DP, Hung SI. HLA-A-31:01 and different types of carbamazepine- induced severe cutaneous adverse reactions: strength of association and meta-Analysis; Drug Hypersensitivity Meeting, 14-18 April 2012, Munich, Germany; 2012.
16. Man CB, Kwan P, Baum L, et al. Association between HLA-B-1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-1018.
17. Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010; 11:349-356.
18. An DM, Wu XT, Hu FY, et al. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B-1502 in a Han Chinese population. Epilepsy Res 2010; 92: 226-230.
19. Hung SI, Chung WH, Liou LB, et al. HLA-B-5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurnol. Proc Natl Acad Sci U S A 2005; 102: 4134-4139.
20. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B-5801 and allopurinol induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmmacogent Genomics 2009; 19: 704-709.
21. Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class 1 alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011; 21: 303-307.
22. Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011; 26: 1-6.
23. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens- Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
24. Kaniwa N, Saitl Y, Aihara M, et al. HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617-1622.
25. Somkrua R, Eickman E, Saokaew S, et al. Association of HLA-B-5801 allele and allopurinl-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-Analysis. BMC Med Genet 2011; 12:118.
26. Tohkin M, Kaniwa N, Saito Y, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics 2013; 13: 60-69.
27. Genin E, Schumacher M, Roujeau JC, et al. Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe. Orphanet J Rare Dis 2011; 6:52.
28. Kim SH, Lee KW, Song WJ, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011; 97: 190-197.
29. Kazeem GB, Cox C, Aponte J, et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 2009; 19: 661-665.
30. Kim SH, Kim M, Lee KW, et al. HLA-B-5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 2010; 11: 879-894.
31. Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123: 1171-1173.
32. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-b-1502 allele in Thai population. Epilepsia 2008; 49: 2087-2091.
33. Wei CY, Chung WH, Huang HW, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129: 1562-1569.
34. Illing Pt, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drugmodified HLA-peptide repertoire. Nature 2012; 486: 548-554.
35. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of theMHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012; 109: 9959-9964.
36. Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel selfpeptides into HLA-B-5701: an autoimmune model for HLA associated drug hypersensitivity. AIDS 2012; 26:F21-F29.
37. Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119:225-230.
38. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nature Med 2008; 14: 1343-1350.
39. Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011; 128: 1266-1276.
40. Bellon T, Alvarez L, Mayorga C, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br J Dermatol 2010; 162: 1014-1022.
41. Morel E, Alvarez L, Cabanas R, et al. Expression of a-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions. Allergy 2011; 66: 360-367.
42. Morel E, Escamochero S, Cabanas R, et al. CD945/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol 2010; 125: 703-710.
43. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012; 13: 1285-1306.
44. Zineh I, Mummaneni P, Lyndly J, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics 2011; 12:1741-1749.
45. Mallal S, Phillips E, CarosiG, et al. HLA-B-5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
46. Chen P, Lin JJ, Lu CS, et al. Carbamazepine induced toxic effects and HLAB -1502 screening in Taiwan. N Engl J Med 2011; 364: 1126-1133.
47. Martin MA, Kelin TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotypes and abacavir dosing. Clin Pharm Ther 2012; 91:734-738; doi: 10.1038/clpt.2011.355.
48. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leuokocyte antigen-B genotyping and allopurinol dosing. Clin Pharm Ther 2013; 93:153-158. 10.1038/clpt.2012.209.
49. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-Analysis. Br J Dermaol 2012; 167: 424-432.
50. Abe R, Yoshioka N, Murata J, et al. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 2009; 151: 514-515.
51. Fujita Y, Yoshioka N, Abe R, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol 2011; 65:65-68.
52. Schneck J, Fagot JP, Sekula P, et al. Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008; 58: 33-40.
53. Lee HY, Dunant A, Sekula P, et al. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol 2012; 167: 555-562.
54. Valeyrie-Allanore l, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010; 163: 847-853.
55. Barbaud A, Collet E, Milpied B, et al. A multicenter study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 2013; 168:555-562; doi: 10.1111/bjd.12125.
56. Lin YT, Chang YC, Hui RC, et al. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/j.1468-3083.
57. Tang YH, Mockenhaupt M, Henry A, et al. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. Clin Exp Allergy 2012; 42: 248-254.
58. Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol 2013; 168: 539-549.
59. Porebski G, Gschwend-Zawodniak A, Pichler WJ. In vitro diagnosis of T-cell mediated drug allergy. Clin Exp Allergy 2011; 4: 461-470.
60. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88: 60-68.